Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · IEX Real-Time Price · USD
3.790
-0.070 (-1.81%)
At close: Mar 28, 2024, 4:00 PM
3.750
-0.040 (-1.06%)
After-hours: Mar 28, 2024, 5:53 PM EDT
Company Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.
It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.
The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors.
Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Enlivex Therapeutics Ltd.
Country | Israel |
Founded | 2005 |
IPO Date | Dec 12, 1995 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 71 |
CEO | Dr. Oren Hershkovitz Ph.D. |
Contact Details
Address: 498 Seventh Avenue, Suite 1810 New York, New York 10018 United States | |
Phone | 212-201-0800 |
Website | enlivex.com |
Stock Details
Ticker Symbol | ENLV |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000919794 |
CUSIP Number | M4130Y106 |
ISIN Number | IL0011319527 |
Employer ID | 95-4102687 |
SIC Code | 7372 |
Key Executives
Name | Position |
---|---|
Shai Novik M.B.A. | Executive Chairman |
Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer |
Prof. Dror Mevorach M.D. | Founder and Chief Scientific and Medical Officer |
Shachar Shlosberger CPA | Chief Financial Officer |
Veronique Amor-Baroukh | Senior Director of Operations |
Sigal Arad | Director of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 3, 2008 | 15-12G | Securities registration termination |
Oct 3, 2008 | 8-K | Current Report |
Oct 2, 2008 | 25-NSE | Filing |
Sep 25, 2008 | 8-K | Current Report |
Sep 25, 2008 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Sep 9, 2008 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Sep 9, 2008 | 425 | Filing |
Sep 5, 2008 | 8-K | Current Report |
Sep 5, 2008 | 425 | Filing |
Aug 27, 2008 | 425 | Filing |